ESPE Abstracts

Background: Numerous studies have highlighted the importance of measuring and achieving optimal adherence to growth hormone treatment in patients with growth disorders. However, there is still a paucity of research on how treatment adherence can be improved in patients with suboptimal adherence.Aim: To classify the causes of suboptimal adherence and collaborate with patients and caregivers to improve adherence.<p cla...

The Easypod™ Connect Observational Study (ECOS) assessed real-time adherence in patients from 24 countries who were receiving recombinant human growth hormone (r-hGH; Saizen®) via easypod™, which is an electronic injection device. Overall, ECOS showed mean adherence was maintained at ~80% for up to 3 years. Here, we assess the adherence to r-hGH administered via easypod™ in the Argentinian cohort of patients from ECOS (NCT01582334).<p class="ab...

Background: The Growzen™ Buddy app was developed to improve adherence to recombinant human growth hormone (r-hGH) therapy among patients with growth disorders. This app sends alerts for injection timings and allows patients and their caregivers to self-monitor growth, develop a treatment routine, improve adherence, and ultimately take ownership of treatment outcomes. The app also contains a library of educational resources designed to empower patients to...